OptiBiotix Health PLC Launch of SlimBiome gummies in USA (4014N)
20 May 2020 - 4:00PM
UK Regulatory
TIDMOPTI
RNS Number : 4014N
OptiBiotix Health PLC
20 May 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Launch of SlimBiome(R) containing gummies in the USA
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces that the Company
has entered into a non-exclusive license agreement for its
SlimBiome(R) trademark with Evolution_18 ("Evolution_18") and
related launch of fibre gummies containing OptiBiotix's
SlimBiome(R) proprietary weight management technology.
Evolution_18 is a US-based company founded by Bobbi Brown who is
known for turning a simple makeup line, Bobbi Brown Essentials,
into a billion-dollar global brand with Estée Lauder Companies (
https://www.nytimes.com/2018/03/31/style/bobbi-brown-just-bobbi.html
). Turning her focus to wellness products, she became a certified
health coach and launched her wellness brand, Evolution_18, which
turned out to be another success story with the listing of its
products at 1,500 Walmart stores as of April 2019 and an estimated
3,000 Walmart stores in September 2019 (
https://foundr.com/money-talks-bobbi-brown ).
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division , c o mmented: "We are very pleased to announce this new
commercial launch in the USA. The partnership with Evolution_18
allows us to collaborate with a brand that is distributed in more
than 3,000 Walmart stores in the USA and also further increase
awareness of the SlimBiome (R) brand. This agreement builds on the
recently announced launch of SlimBiome (R) containing products in
the UK with Holland & Barrett (RNS: 7 January 2020), a
partnership with OptiPharm, whose Optislim is Australia's best
selling weight management brand (RNS: 31 March 2020), as well the
signature of a non-exclusive agreement with Smart For Life (RNS: 4
May 2020) which made SlimBiome (R) available to customers at
Walmart in the USA and Costco in Canada in early May.
"This agreement with Evolution_18 demonstrates our ability to
negotiate deals with increasingly large partners around the world.
As announced on 18 May 2020, this has led to a change in the nature
of our discussions with prospective commercial partners as we no
longer have to demonstrate the validity or commercial value of our
science leading to more deals (70%) expected to deliver revenues in
the first year of agreement compared to 2019 (35%)."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRSFMFMUESSELI
(END) Dow Jones Newswires
May 20, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024